PTD unknown

Peptech / Diversys / Domantis

  1. lb
    91 Posts.
    Domain Antibody Company Takes Premises in Cambridge UK and Cambridge MA, USA

    Cambridge, UK and USA, May 1, 2002... Diversys, a biotechnology company formed in December 2000, today announced that it has changed its name to Domantis. The new name recognizes the Company's focus on the development of its core Domain Antibody technology, primarily for therapeutic products. Domantis intends to develop a pipeline of fully human Domain Antibody therapeutics both in conjunction with partners and for generation of its own product leads.
    Domantis CEO Robert Connelly said, "Our first full year was highly productive as we transferred the Domain Antibody technology from the Medical Research Council's laboratories to our own labs, strengthened our intellectual property position, assembled an experienced team of scientists and executives, signed a collaboration agreement with Peptech Ltd, and initiated our first Domain Antibody therapeutic programs. The $20 million we raised last year will allow us to aggressively develop our Domain Antibody pipeline."
    Domantis has established a research and development facility on the Granta Park in Cambridge, UK and has opened offices in Cambridge, MA, in the US for business development and finance activities. The Company has now grown to 22 employees and recent hires have included Mr Jasper Clube as Director of Intellectual Property. Mr Clube, a qualified European Patent Attorney and UK Chartered Patent Attorney, joined Diversys after six years with AstraZeneca and five years in a UK patent firm.
    Ian Tomlinson, Founder and Chief Scientific Officer of Domantis further stated, "We believe that fully human Domain Antibodies with their unique expression and binding characteristics will make ideal products. Their small size allows them to be used as building blocks in a number of different product configurations. Domain Antibodies should be able to be used in the same way as full antibodies but with significant cost advantages and administered via non-intravenous routes not amenable to full antibodies."
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.